Discounted Cash Flow (DCF) Analysis Levered
Infinity Pharmaceuticals, Inc. (INFI)
$0.1801
-0.00 (-1.10%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 6 | 22.15 | 3.05 | 1.72 | 1.86 | 2.54 | 3.48 | 4.76 | 6.51 | 8.91 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -36.71 | -4.71 | -41.53 | -35.74 | -40.62 | -31.83 | -43.56 | -59.60 | -81.55 | -111.59 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.04 | -0.16 | -0.02 | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | -0.05 | -0.06 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -36.75 | -4.87 | -41.55 | -35.75 | -40.63 | -31.85 | -43.58 | -59.63 | -81.60 | -111.66 |
Weighted Average Cost Of Capital
| Share price | $ 0.1,801 |
|---|---|
| Beta | 1.350 |
| Diluted Shares Outstanding | 85.60 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 12.53% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 10.065 |
| Total Debt | 1.44 |
| Total Equity | 15.42 |
| Total Capital | 16.85 |
| Debt Weighting | 8.52 |
| Equity Weighting | 91.48 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 6 | 22.15 | 3.05 | 1.72 | 1.86 | 2.54 | 3.48 | 4.76 | 6.51 | 8.91 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.71 | -4.71 | -41.53 | -35.74 | -40.62 | -31.83 | -43.56 | -59.60 | -81.55 | -111.59 |
| Capital Expenditure | -0.04 | -0.16 | -0.02 | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | -0.05 | -0.06 |
| Free Cash Flow | -36.75 | -4.87 | -41.55 | -35.75 | -40.63 | -31.85 | -43.58 | -59.63 | -81.60 | -111.66 |
| WACC | ||||||||||
| PV LFCF | -28.88 | -35.84 | -44.46 | -55.17 | -68.45 | |||||
| SUM PV LFCF | -232.81 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 10.28 |
| Free cash flow (t + 1) | -113.89 |
| Terminal Value | -1,375.48 |
| Present Value of Terminal Value | -843.28 |
Intrinsic Value
| Enterprise Value | -1,076.08 |
|---|---|
| Net Debt | -79.29 |
| Equity Value | -996.79 |
| Shares Outstanding | 85.60 |
| Equity Value Per Share | -11.65 |